ArticleIndian journal of ophthalmology2017
Efficacy of 1% atropine eye drops in retarding progressive axial myopia in Indian eyes.
Article in Indian journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM Study).Indian journal of ophthalmology · 2022Trial
- Timing of height growth peaks and axial elongation in atropine-treated myopic children.BMC ophthalmology · 2026Article
- Therapeutic effects of orthokeratology lens combined with 0.01% atropine eye drops on juvenile myopia.Arquivos brasileiros de oftalmologia · 2023Article
- Myopia in India.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- A Review of Intraocular Pressure (IOP) and Axial Myopia.Journal of ophthalmology · 2022Review
- Convergence excess consecutive esotropia associated with 0.01% atropine eye drops usage in patients operated for intermittent exotropia.Indian journal of ophthalmology · 2020Article
- Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Consensus statement and guidelines for use of dilute atropine sulphate in myopia control.Indian journal of ophthalmology · 2019Review
- Physical, chemical, and microbiological stability study of diluted atropine eye drops.Journal of pharmaceutical health care and sciences · 2019Article
- Systematic Analysis of Transcriptomic Profile of the Effects of Low Dose Atropine Treatment on Scleral Fibroblasts using Next-Generation Sequencing and Bioinformatics.International journal of medical sciences · 2019Article
- Allergic reactions to atropine eye drops for retardation of progressive myopia in children.Indian journal of ophthalmology · 2018Article
- Prevention of Progression in Myopia: A Systematic Review.Diseases (Basel, Switzerland) · 2018Review
- Conquering myopia: Have we hit pay dirt?Indian journal of ophthalmology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study is to assess the efficacy of 1% atropine eye drops for the retardation of progressive axial myopia in Indian eyes.
methodsThis prospective interventional cohort study included children aged 5-16 years. Both the eyes of myopic children with progressive increase of ≥-0.5D sphere/year with the best-corrected vision of ≥6/6 were treated with once a day application of 1% atropine eye drops and progressive addition photogray lenses. The progression of myopia after 1-year follow-up was analyzed.
resultsSixty eyes of thirty myopes were included in the study. The mean age was 10 years and 15 were girls. The mean baseline sphere was -5.2D (-2.5D--13D). Mean duration of follow-up was 23 months (12-36 months). The baseline rate of progression was reduced from -0.6D/year (range -0.5D/year to -3D/year) to -0.2D/year (range 0D/year to -1.5D/year) after atropine therapy. Seventeen patients (57%) had to use the atropine in the daytime to reach the target progression of P = 0.6). The efficacy of atropine drops did not have a correlation with the age of the patients or the magnitude of baseline myopia (Pearson's r = 0).
conclusion1% atropine eye drops was well tolerated and efficacious for the retardation of progressive myopia in Indian eyes. Effectiveness was better with daytime application. Further studies are necessary to assess the role of 1% atropine in the rapid progressors and patients poorly responding to low-dose atropine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.